Keyphrases
Glioblastoma
88%
High-grade Glioma
55%
Tumor
54%
Bevacizumab
43%
Newly Diagnosed Glioblastoma
39%
Radiation Therapy
37%
Temozolomide
35%
Brain Tumor
33%
Glioblastoma multiforme
30%
Primary Brain Tumor
27%
Overall Survival
26%
Radiotherapy
25%
NRG Oncology
23%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
21%
Radiation Therapy Oncology Group
20%
Chemotherapy
19%
Glioma
19%
Tumor Treating Fields
18%
Dynamic Contrast-enhanced
17%
Progression-free Survival
17%
Recurrent Glioblastoma
17%
Magnetic Resonance Imaging
16%
Phase II Study
15%
Recursive Partitioning Analysis
14%
Hazard Ratio
14%
Southwest Oncology Group
13%
Surgical Resection
13%
Brain Metastases
13%
Oncology
13%
Immune Checkpoint Inhibitors
12%
Vasogenic Edema
11%
Neuro-oncology
11%
Phase II Trial
11%
Anaplastic Astrocytoma
11%
Cisplatin
11%
Newly Diagnosed
10%
Malignant Glioma
10%
Failed Repair
10%
Low-grade Glioma
10%
Patient Survival
10%
Confidence Interval
9%
Median Overall Survival
9%
Tumor Progression
9%
Methylation Status
9%
Adult Patients
9%
Partial Response
9%
Retrospective Analysis
9%
Carmustine
9%
Central Nervous System Tumors
9%
Post-marketing Safety Surveillance
9%
Medicine and Dentistry
Glioblastoma
100%
Neoplasm
64%
Ganglioglioma
62%
Radiation Therapy
46%
Oncology
40%
Intracranial Tumor
35%
Temozolomide
34%
Overall Survival
31%
Bevacizumab
30%
Magnetic Resonance Imaging
27%
Malignant Neoplasm
24%
Progression Free Survival
22%
Diseases
20%
Neuro-Oncology
15%
Brain Metastasis
15%
Meningioma
14%
Metastatic Carcinoma
13%
Central Nervous System Tumor
11%
Immunotherapy
11%
Clinical Trial
11%
Cisplatin
11%
Neurologic Disease
11%
Methylation
10%
External Beam Radiotherapy
10%
Treatment Response
10%
Recurrent Disease
10%
Cancer
10%
Oligoastrocytoma
9%
DNA Mismatch Repair
9%
Hazard Ratio
9%
Immune Checkpoint Inhibitor
9%
Group Trial
9%
Nivolumab
9%
Medulloblastoma
9%
Encephalitis
9%
Pembrolizumab
9%
Tumor Treating Fields
9%
Oligodendroglioma
9%
Carmustine
9%
Germ Cell
9%
Arm
9%
Recursive Partitioning
8%
Brain Cancer
8%
Neurological Complication
7%
T Cell
7%
Tumor Progression
7%
Survival Rate
6%
Re-Irradiation
6%
Magnetic Resonance Imaging
6%
Central Nervous System
6%